Post
of 161,337
Leronlimab & "Any ICI" related to Creativ patent:
Under the 8th Embodiment:
"In certain of the relevant embodiments and aspects defined above, the immune checkpoint inhibitor is one or more of a PD-L1 antagonist, PD-1 antagonist, and a CTLA-4 antagonist."
__
All the Embodiments are good & patent every step after Leronlimab causes PD-L1 expression.
__
Anti-Cancer Agents:
" The anti-cancer agents are only limited in that they be compatible with the immune checkpoint inhibitors that are also administered to the subject."
Dr. J reinforcing "any ICI" again, comes to mind.
__
Source of Cells:
"The cells used in the methods of the present invention include one or more of CTCs, EMTCTCs, CAMLs, and CAVEs. Thus, the methods may be performed using one, two, three or all four of these types of circulating cells."
Once Leronlimab causes signaling, Creatv is
patent locked on which liquid biopsy circulating cells, for an ICI dosing.
Filed:
April 26, 2022
Date of Patent:
November 25, 2025
patents.justia.com/patent/1...
Under the 8th Embodiment:
"In certain of the relevant embodiments and aspects defined above, the immune checkpoint inhibitor is one or more of a PD-L1 antagonist, PD-1 antagonist, and a CTLA-4 antagonist."
__
All the Embodiments are good & patent every step after Leronlimab causes PD-L1 expression.
__
Anti-Cancer Agents:
" The anti-cancer agents are only limited in that they be compatible with the immune checkpoint inhibitors that are also administered to the subject."
Dr. J reinforcing "any ICI" again, comes to mind.
__
Source of Cells:
"The cells used in the methods of the present invention include one or more of CTCs, EMTCTCs, CAMLs, and CAVEs. Thus, the methods may be performed using one, two, three or all four of these types of circulating cells."
Once Leronlimab causes signaling, Creatv is
patent locked on which liquid biopsy circulating cells, for an ICI dosing.
Filed:
April 26, 2022
Date of Patent:
November 25, 2025
patents.justia.com/patent/1...
3